Publication: Implications of ACC/AHA Versus ESC/EAS LDL-C Recommendations for Residual Risk Reduction in ASCVD: A Simulation Study From DA VINCI.
No Thumbnail Available
Identifiers
Date
2022-05-14
Authors
Vallejo-Vaz, Antonio J
Bray, Sarah
Villa, Guillermo
Brandts, Julia
Kiru, Gaia
Murphy, Jennifer
Banach, Maciej
De Servi, Stefano
Gaita, Dan
Gouni-Berthold, Ioanna
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Metrics
Export
Abstract
Low-density lipoprotein cholesterol (LDL-C) recommendations differ between the 2018 American College of Cardiology/American Heart Association (ACC/AHA) and 2019 European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) guidelines for patients with atherosclerotic cardiovascular disease (ASCVD) ( DA VINCI was a cross-sectional observational study of patients prescribed lipid-lowering therapy (LLT) across 18 European countries. Ten-year cardiovascular risk (CVR) was predicted among ASCVD patients receiving stabilized LLT. For patients with LDL-C ≥ 70 mg/dl, the absolute LDL-C reduction required to achieve an LDL-C of Of the 2039 patients, 61% did not achieve LDL-C In ASCVD patients, achieving ESC/EAS LDL-C goals could result in a 2% additional ARR over 10 years versus the ACC/AHA approach.
Description
MeSH Terms
DeCS Terms
CIE Terms
Keywords
Atherosclerotic cardiovascular disease, Cardiovascular disease prevention, Cardiovascular risk, LDL-C, Lipid-lowering, Statins